May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Use of Pamidronate and Supplemental Saline to Reduce Toxicity and Increase Effectiveness of Calcitriol in a Retinoblastoma Model
Author Affiliations & Notes
  • A. Kulkarni
    Ophthalmology, Univ. of Wisconsin, Madison, Madison, WI
  • E.M. Gates
    Ophthalmology, Univ. of Wisconsin, Madison, Madison, WI
  • S.R. Darjatmoko
    Ophthalmology, Univ. of Wisconsin, Madison, Madison, WI
  • D.M. Albert
    Ophthalmology, Univ. of Wisconsin, Madison, Madison, WI
  • Footnotes
    Commercial Relationships  A. Kulkarni, None; E.M. Gates, None; S.R. Darjatmoko, None; D.M. Albert, None.
  • Footnotes
    Support  NEI EYO1917; Research to Prevent Blindness; and Bone Care International Inc.
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2811. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Kulkarni, E.M. Gates, S.R. Darjatmoko, D.M. Albert; Use of Pamidronate and Supplemental Saline to Reduce Toxicity and Increase Effectiveness of Calcitriol in a Retinoblastoma Model . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2811.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : 1. To evaluate the efficacy and toxicity of therapy with calcitriol and pamidronate in athymic mice with subcutaneous Y–79 human retinoblastoma tumors. Pamidronate is a nitrogenous bisphosphonate which acts through the HMG CoA–reductase pathway and potentiates osteoclast–induced apoptosis. 2. To reduce toxic effects of calcitriol by using supplemental saline injection based on its use in treating acute hypercalcemia in humans.

Methods: : 42 athymic mice were subcutaneously injected with 5 x 106 human Y79 retinoblastoma cells. Animals were randomized into four groups: group 1 – 0.1 ml vehicle and 0.25 ml saline (negative control); group 2 – 0.05µg of calcitriol in 0.1 ml of vehicle and 0.25 ml saline; group 3 – 0.05µg of calcitriol in 0.1 ml of vehicle and 180µg of pamidronate in 0.25 ml of saline; group 4 – 0.05µg of calcitriol in 0.1 ml of vehicle without saline (positive control). The calcitriol and vehicle were administered intraperitoneally whereas the pamidronate and saline were injected subcutaneously 5 times a week for 4 weeks. Tumor size and body weights were recorded 2 times a week.

Results: : The mean change in tumor volume was as follows: For calcitriol treated animals (group 2) 658.23 mm3 (p=0.0056); for combination therapy of calcitriol and pamidronate (group 3) 364 mm3 (p=0.0003). Both were significantly less than the mean change in tumor volume of 1371.78 mm3 in the negative controls (group 1). There was an average weight loss of 0.07 g in group 3 as compared to average weight gains of 3.72 g in group 2 (p=0.0005) and 3.77 g in group 1 (p=0.0003). Moreover the average weight gain and absence of mortality in group 2 receiving calcitriol and saline was highly significant (p=0.0001) as compared to the positive control receiving calcitriol with no saline (group 4). This latter group showed an average weight loss of 4.03 g and 90 % mortality.

Conclusions: : Calcitriol inhibits tumor growth in a Y79 xenograft model in athymic mice and a co–administration of saline significantly reduces the morbidity and mortality. The addition of pamidronate to calcitriol produced further significant reduction of tumor size but increased toxicity.

Keywords: retinoblastoma • oncology • pathobiology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×